Ameritas Investment Partners Inc. Sells 181 Shares of Bio-Rad Laboratories, Inc. $BIO

Ameritas Investment Partners Inc. reduced its stake in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) by 4.8% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 3,611 shares of the medical research company’s stock after selling 181 shares during the quarter. Ameritas Investment Partners Inc.’s holdings in Bio-Rad Laboratories were worth $871,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of the company. First Eagle Investment Management LLC raised its holdings in Bio-Rad Laboratories by 60.7% in the second quarter. First Eagle Investment Management LLC now owns 2,517,313 shares of the medical research company’s stock worth $607,478,000 after purchasing an additional 951,123 shares during the period. Ariel Investments LLC grew its stake in Bio-Rad Laboratories by 29.3% in the first quarter. Ariel Investments LLC now owns 724,660 shares of the medical research company’s stock valued at $176,498,000 after acquiring an additional 164,136 shares during the period. Dimensional Fund Advisors LP boosted its holdings in shares of Bio-Rad Laboratories by 17.5% in the first quarter. Dimensional Fund Advisors LP now owns 877,040 shares of the medical research company’s stock valued at $213,608,000 after buying an additional 130,921 shares during the period. Allianz Asset Management GmbH grew its holdings in shares of Bio-Rad Laboratories by 231.8% during the second quarter. Allianz Asset Management GmbH now owns 54,239 shares of the medical research company’s stock worth $13,089,000 after buying an additional 37,893 shares in the last quarter. Finally, Arnhold LLC bought a new position in shares of Bio-Rad Laboratories during the second quarter worth about $8,394,000. 65.24% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

BIO has been the subject of several recent research reports. Wall Street Zen cut shares of Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a report on Saturday, November 22nd. Zacks Research upgraded Bio-Rad Laboratories from a “strong sell” rating to a “hold” rating in a research note on Tuesday, August 26th. Citigroup boosted their price target on Bio-Rad Laboratories from $350.00 to $375.00 and gave the stock a “buy” rating in a research report on Thursday, October 30th. Wells Fargo & Company boosted their price objective on shares of Bio-Rad Laboratories from $265.00 to $340.00 and gave the stock an “equal weight” rating in a research note on Thursday, October 30th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Bio-Rad Laboratories in a research report on Tuesday. Three research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $358.50.

Bio-Rad Laboratories Trading Down 1.6%

Shares of BIO stock opened at $326.95 on Friday. The stock has a market cap of $8.82 billion, a P/E ratio of -13.45 and a beta of 1.04. Bio-Rad Laboratories, Inc. has a 1 year low of $211.43 and a 1 year high of $373.69. The company has a current ratio of 5.12, a quick ratio of 3.67 and a debt-to-equity ratio of 0.17. The stock has a 50 day simple moving average of $308.31 and a 200 day simple moving average of $274.75.

Bio-Rad Laboratories (NYSE:BIO) last posted its quarterly earnings data on Wednesday, October 29th. The medical research company reported $2.26 EPS for the quarter, missing analysts’ consensus estimates of $2.30 by ($0.04). The company had revenue of $653.00 million for the quarter, compared to the consensus estimate of $651.30 million. Bio-Rad Laboratories had a positive return on equity of 4.18% and a negative net margin of 26.43%.Bio-Rad Laboratories’s revenue was up .5% on a year-over-year basis. During the same quarter last year, the business earned $2.01 EPS. Bio-Rad Laboratories has set its FY 2025 guidance at EPS. On average, research analysts predict that Bio-Rad Laboratories, Inc. will post 10.81 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, EVP James Barry sold 700 shares of the business’s stock in a transaction that occurred on Thursday, November 6th. The shares were sold at an average price of $306.18, for a total value of $214,326.00. Following the completion of the transaction, the executive vice president directly owned 510 shares in the company, valued at approximately $156,151.80. The trade was a 57.85% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 17.83% of the stock is currently owned by corporate insiders.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.